Overview

Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate efficacy and safety of naftopidil in patient with neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia.

Phase:

Phase 4

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Naftopidil
Tamsulosin